It was found that HER2 mediated inhibition for Beclin 1 autophagy might be beneficial to HER2-mediated tumorigenesis, and the strategies blocking HER2 / Beclin 1 binding or increased autophagy were promising on curing HER2-positive BC patients. The gene discussed is ERBB2; the disease is breast cancer.